Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 2/3 2Phase 1/2 1

Status

Unknown 18Recruiting 6Completed 6Active not recruiting 4Not yet recruiting 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Carcinoma, Hepatocellular 2Stomach Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × apatinib × Clear all
NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Active not recruiting
592 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07371910 2026-01-28

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Active not recruiting
200 enrolled
Breast

Breast Neoplasms

NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Sun Yat-sen University

Phase 3 Active not recruiting
214 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
687 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡